false
0001763950
0001763950
2025-09-19
2025-09-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 19, 2025
Lantern
Pharma Inc.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-39318 |
|
46-3973463 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification
No.) |
1920
McKinney Avenue, 7th Floor
Dallas,
Texas |
|
75201 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
(972)
277-1136
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act: Common Stock
| Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
| Common
Stock, $0.0001 par value |
|
LTRN |
|
The
Nasdaq Stock Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.07 Submission of Matters to a Vote of Security Holders.
On
September 19, 2025, Lantern Pharma Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders, for the purposes of:
| |
● |
Electing
six directors, each to serve until our 2026 Annual Meeting of Stockholders; |
| |
|
|
| ● | Approving
the one-time repricing of certain stock options granted under the Second Amended and Restated
Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended; and |
| | | |
| |
● |
Ratifying
the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. |
All
of the persons nominated to serve on our board of directors, namely Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini,
Lee T. Schalop and David S. Silberstein, were elected to our board of directors, with shares voted as follows:
| Name | |
For | | |
Withheld | | |
Broker Non-Vote | |
| Donald Jeff Keyser | |
| 2,213,848 | | |
| 32,958 | | |
| 5,189,274 | |
| Panna Sharma | |
| 2,212,199 | | |
| 34,607 | | |
| 5,189,274 | |
| Vijay Chandru | |
| 2,202,401 | | |
| 44,405 | | |
| 5,189,274 | |
| Maria Maccecchini | |
| 2,214,833 | | |
| 31,973 | | |
| 5,189,274 | |
| Lee T. Schalop | |
| 2,213,670 | | |
| 33,136 | | |
| 5,189,274 | |
| David S. Silberstein | |
| 2,213,088 | | |
| 33,718 | | |
| 5,189,274 | |
Our
stockholders approved the one-time repricing of certain stock options granted under the Second Amended and Restated Lantern Pharma Inc.
2018 Equity Incentive Plan, as amended, with shares voted as follows:
| For | |
| 1,458,333 | |
| Against | |
| 758,870 | |
| Abstain | |
| 29,603 | |
| Broker Non-Votes | |
| 5,189,274 | |
In
addition, our stockholders ratified the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal
year ending December 31, 2025, with shares voted as follows:
| For | |
| 7,365,922 | |
| Against | |
| 43,732 | |
| Abstain | |
| 26,426 | |
There
were no broker non-votes on the ratification of our independent registered public accounting firm.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
Lantern
Pharma Inc., |
| |
A
Delaware Corporation |
| |
|
| Dated:
September 23, 2025 |
By: |
/s/
David R. Margrave |
| |
|
David
R. Margrave, Chief Financial Officer |
